Of these four vaccines, the best results were obtained with PV-1950, which simultaneously targets three B cell epitopes of this pathological molecule, showing the most significant reduction of α-Synuclein and neurodegeneration in the brains of vaccinated hα-Syn D line mice.
“The development of a safe and immunogenic vaccine targeting all forms of pathological α-Synuclein is IMM’s goal. Importantly, our most effective vaccine, PV-1950, generated strong antibody production, reducing pathological α-Synuclein and improving motor deficits in a mouse model of disease is ready to be tested in preventive clinical trials.
“The PV-1950 has two versions – one based on DNA and one on recombinant protein. Complementary prime-boost immunization with heterologous DNA and protein vaccines is an alternative and promising approach to elicit greater antibody responses.”
— Dr. Agadjanyan
PD is the second most prevalent neurodegenerative disorder of aging that affects both motor and cognitive function. The institute looks to the vaccine-based preventative treatment of neurodegenerative diseases such as PD, DLB, and AD. An immunogenic vaccine could be the most effective way to block/inhibit the aggregation of toxic α-Synuclein protein from the accumulation and spreading in the brains and halt or delay the disease, said IMM.
“α-Synuclein is a neuronal protein that is linked genetically and neuropathologically to various α-synucleopathies, including Parkinson’s disease (PD). Once pathology begins, it becomes virtually impossible to stop it, so using MultiTEP platform-based vaccine from IMM Nuravax want to halt or delay the disease in people at risk of α-synucleopathies.”
— Roman Kniazev